Omeros OMER Stock
Omeros Price Chart
Omeros OMER Financial and Trading Overview
| Omeros stock price | 17.88 USD |
| Previous Close | 16.29 USD |
| Open | 16.3 USD |
| Bid | 9.39 USD x 200 |
| Ask | 16.29 USD x 200 |
| Day's Range | 16.2 - 17.51 USD |
| 52 Week Range | 6.24 - 21.24 USD |
| Volume | 894.35K USD |
| Avg. Volume | 1.68M USD |
| Market Cap | 1.27B USD |
| Beta (5Y Monthly) | 2.57 |
| PE Ratio (TTM) | 14.336065 |
| EPS (TTM) | 1.22 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.5 USD |
OMER Valuation Measures
| Enterprise Value | 1.34B USD |
| Trailing P/E | 14.336065 |
| Forward P/E | 14.219512 |
| PEG Ratio (5 yr expected) | 0.81 |
| Price/Sales (ttm) | 32.951736 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 34.983 |
| Enterprise Value/EBITDA | -18.691 |
Trading Information
Omeros Stock Price History
| Beta (5Y Monthly) | 2.57 |
| 52-Week Change | 104.64% |
| S&P500 52-Week Change | 11.40% |
| 52 Week High | 21.24 USD |
| 52 Week Low | 6.24 USD |
| 50-Day Moving Average | 18.5 USD |
| 200-Day Moving Average | 13.38 USD |
OMER Share Statistics
| Avg. Volume (3 month) | 1.68M USD |
| Avg. Daily Volume (10-Days) | 1.18M USD |
| Shares Outstanding | 72.39M |
| Float | 69.29M |
| Short Ratio | 7.54 |
| % Held by Insiders | 4.08% |
| % Held by Institutions | 51.34% |
| Shares Short | 11.38M |
| Short % of Float | 16.29% |
| Short % of Shares Outstanding | 15.72% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 324.88% |
| Operating Margin (ttm) | 0.25% |
| Gross Margin | 38.34% |
| EBITDA Margin | -187.16% |
Management Effectiveness
| Return on Assets (ttm) | -18.67% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 38.42M USD |
| Revenue Per Share (ttm) | 0.55 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 14.73M USD |
| EBITDA | -71913000 USD |
| Net Income Avi to Common (ttm) | 116.53M USD |
| Diluted EPS (ttm) | 1.22 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 131.95M USD |
| Total Cash Per Share (mrq) | 1.82 USD |
| Total Debt (mrq) | 296.87M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 1.951 |
| Book Value Per Share (mrq) | -0.712 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -68672000 USD |
| Levered Free Cash Flow (ttm) | 183.31M USD |
Profile of Omeros
| Country | United States |
| State | WA |
| City | Seattle |
| Address | The Omeros Building |
| ZIP | 98119 |
| Phone | 206 676 5000 |
| Website | https://www.omeros.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 175 |
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Q&A For Omeros Stock
What is a current OMER stock price?
Omeros OMER stock price today per share is 17.88 USD.
How to purchase Omeros stock?
You can buy OMER shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Omeros?
The stock symbol or ticker of Omeros is OMER.
Which industry does the Omeros company belong to?
The Omeros industry is Biotechnology.
How many shares does Omeros have in circulation?
The max supply of Omeros shares is 72.39M.
What is Omeros Price to Earnings Ratio (PE Ratio)?
Omeros PE Ratio is 14.65573700 now.
What was Omeros earnings per share over the trailing 12 months (TTM)?
Omeros EPS is 1.22 USD over the trailing 12 months.
Which sector does the Omeros company belong to?
The Omeros sector is Healthcare.
Omeros OMER included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
|
- | |||||
US Tech Composite
IXIC
US
|
26549.85 USD — |
+0.27
|
7.14B USD — | 26414.92 USD — | 26587.34 USD — | — - | 7.14B USD — |
|
US Tech Biotechnology Total Retu
XNBI
US
|
7928.59 USD — |
+1.48
|
— — | 7720.37 USD — | 7943.44 USD — | — - | — — |
|
US Tech Global Market Composite
NQGM
US
|
2049.7 USD — |
+1.04
|
— — | 2019.7 USD — | 2050.1 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
7256.33 USD — |
+1.48
|
— — | 7065.77 USD — | 7269.93 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1368.59 USD — |
+1.45
|
— — | 1337.51 USD — | 1371.51 USD — | — - | — — |
|
US Tech Composite Total Return
XCMP
US
|
32799.1 USD — |
+0.27
|
— — | 32632.41 USD — | 32845.41 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
